Reply to: Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure

被引：0
|
作者：
Perez-Belmonte, Luis M. [1 ,2 ,3 ,4 ]
Miramontes-Gonzalez, Jose P. [5 ,6 ]
Osuna-Sanchez, Julio [3 ,7 ]
Lara, Jose P. [3 ]
Gomez-Huelgas, Ricardo [1 ,8 ]
机构：
[1] Univ Malaga UMA, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga, Serv Med Interna, Malaga, Spain
[2] Hosp Helicopteros Sanitarios, Serv Med Interna, Marbella, Spain
[3] Univ Malaga UMA, Ctr InvesT Med Sanitarias CIMES, Unidad Neurofis Congnit, Inst Invest Biomed Malaga IBIMA,Fac Med, Malaga, Spain
[4] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Cardiovasc, Madrid, Spain
[5] Univ Valladolid, Hosp Univ Rio Hortega, Serv Med Interna, Fac Med,Dept Med, Valladolid, Spain
[6] Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain
[7] Hosp Comarcal La Axarquia, Serv Med Interna, Malaga, Spain
[8] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obsidad & Nutr C, Madrid, Spain
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2022年 / 70卷 / 05期
关键词：
D O I：
10.1111/jgs.17703
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
This letter comments on the letter by .
引用
收藏
页码：1585 / 1589
页数：5
相关论文
共 50 条
  • [1] Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure
    Ismayilov, Rashad
    Balci, Cafer
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (05) : 1584 - 1585
  • [2] Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure
    Perez-Belmonte, Luis M.
    Sanz-Canovas, Jaime
    Millan-Gomez, Mercedes
    Osuna-Sanchez, Julio
    Lopez-Sampalo, Almudena
    Ricci, Michele
    Jimenez-Navarro, Manuel
    Lopez-Carmona, Maria D.
    Bernal-Lopez, Maria Rosa
    Barbancho, Miguel A.
    Lara, Jose P.
    Gomez-Huelgas, Ricardo
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (03) : 862 - 871
  • [3] Empagliflozin in patients hospitalized for acute heart failure
    Ponikowski, Piotr
    Biegus, Jan
    EUROPEAN HEART JOURNAL, 2022, 43 (41) : 4219 - 4221
  • [4] Progress of patients hospitalized with acute heart failure treated with empagliflozin
    Raya-Cruz, Manuel
    Jurado, Javier Gasc on
    Torre, Gonzalo Olalla de la
    Ufar, Nicolas Mont
    Sanchez, Agustin Rodriguez
    Delgado, Francisco G. omez
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, : e240027
  • [5] Effect of empagliflozin as add-on therapy on transtubular potassium concentration gradient in patients with type 2 diabetes hospitalized for acute decompensated heart failure
    Tamaki, S.
    Yamada, T.
    Watanabe, T.
    Morita, T.
    Furukawa, Y.
    Kawasaki, M.
    Kikuchi, A.
    Kawai, T.
    Seo, M.
    Abe, M.
    Nakamura, J.
    Yamamoto, K.
    Fukunami, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1228 - 1228
  • [6] Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
    Perez-Belmonte, Luis M.
    Ricci, Michele
    Sanz-Canovas, Jaime
    Millan-Gomez, Mercedes
    Osuna-Sanchez, Julio
    Isabel Ruiz-Moreno, M.
    Bernal-Lopez, M. Rosa
    Lopez-Carmona, Maria D.
    Jimenez-Navarro, Manuel
    Gomez-Doblas, Juan J.
    Lara, Jose P.
    Gomez-Huelgas, Ricardo
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [7] Utilization of Empagliflozin in Patients with Type 2 Diabetes Mellitus and Congestive Heart Failure
    Alvarez, Carlos A.
    Perkins, Aaron
    Sigler, Meredith A.
    Yang, Hui
    Caberwal, Harjeet
    Ebrahimi, Ramin
    DIABETES, 2023, 72
  • [8] Mechanistic insights into the effects of empagliflozin in patients with type 2 diabetes and heart failure
    Elrakaybi, A.
    Laubner, K.
    Zhou, Q.
    Paeth, G.
    Schmitt, H.
    Hug, M. J.
    Seufert, J.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S24 - S24
  • [9] Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure
    Weir, Daniala L.
    Abrahamowicz, Michal
    Beauchamp, Marie-Eve
    Eurich, Dean T.
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2653 - 2660
  • [10] Empagliflozin versus dapagliflozin for primary prevention of heart failure in patients with type 2 diabetes
    Arbel, R. Ronen
    Aboalhasan, E.
    Hammerman, A.
    Azuri, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 95 - 95
12345